A technical note from the Ministry of Health finalized the use and production of the AstraZeneca vaccine, produced in Brazil by FioCruz, due to the risks of thrombosis attributed to the vaccine that was applied to 115.6 million Brazilians until January 2022.
The recommendation was published on December 27, 2022, but it went unnoticed. The document says that both AstraZeneca and Janssen are not applied to people under 40 years old and that the other available vaccines are given preference.
The justification is the cases of thrombosis syndrome with thrombocytopenia (TST) that were identified in other countries at the beginning of vaccination and that also had cases registered in Brazil.
The document says that 98 cases of STT related to AstraZeneca were notified in the e-SUS, of which 34 had level 1 of diagnostic certainty (confirmed cases), 17 cases with level 2 (probable cases) and 47 cases with level 3 (possible cases). ). Women under 40 were the main victims.
– Among the probable and confirmed cases (levels 1 and 2 of diagnostic certainty), it is observed that almost all cases occurred with the Astrazeneca and Janssen vaccines, with similar incidences between them, and with the first dose of the vaccine. Only 2 cases occurred with the second dose and, more recently, cases have been observed with booster doses – says an excerpt from the technical note 393/2022.
In view of this new recommendation, the Ministry of Health chose not to renew the contract with FioCruz, thus, vaccines are no longer produced and used in Brazil.
